Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia

用于路易体痴呆临终诊断的外周组织生物标志物

基本信息

批准号：
10401974
负责人：
SHU G. CHEN
金额：
$ 97.52万
依托单位：
CASE WESTERN RESERVE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10401974
关键词：
Address Affect Anosmia Antibodies Award Biological Biological Assay Biological Markers Biopsy Blood specimen Brain COVID-19 COVID-19 pandemic COVID-19 susceptibility COVID-19 testing Clinic Clinical Clinical assessments Computerized Medical Record Control Groups Dementia Dementia with Lewy Bodies Detection Development Diagnosis Diagnostic Differential Diagnosis Disease Disease Progression Early Diagnosis Enrollment Evaluation Foundations Funding Future Goals Hospitalization Impaired cognition Lewy Body Dementia Lewy Body Disease Literature Long-Term Effects MRI Scans Magnetic Resonance Imaging Measures Molecular Motor Neurologic Neurologic Symptoms Olfactory Mucosa Outcome Parents Parkinson&apos s Dementia Parkinsonian Disorders Patient Care Patients Peripheral Recording of previous events Records Reporting Research Risk Factors SARS-CoV-2 infection Saliva Severities Severity of illness Site Skin Skin Tissue Standardization Study Subject Symptoms Tauopathies Testing Therapeutic Therapeutic Intervention Time United States National Institutes of Health Visit alpha synuclein bioinformatics tool brain health clinical Diagnosis comorbidity diagnostic biomarker follow up assessment follow-up human subject illness length improved insight interest nasal swab nervous system disorder neuroimaging marker neurophysiology neuropsychiatric symptom non-motor symptom preventive intervention progression marker protein aggregation recruit research clinical testing response synucleinopathy tau Proteins tau aggregation tissue biomarkers vaccination outcome viral RNA

项目摘要

Abstract This supplemental application will examine the effects of COVID-19 on the disease severity and changes in diagnostic biomarkers of Lewy body dementia (LBD) affecting 1.4 million people in the U.S. Recent studies have shown that patients with dementia are more susceptible to COVID-19 infection, however, the effects of COVID- 19 infection on the severity and progression of dementia has yet to be systematically examined. Further, it is unclear how overlapping symptoms between Lewy body diseases and those reported for COVID-19 including anosmia and various neurological symptoms might further complicate clinical evaluation and diagnosis of LBD. We will address this research question by testing patients with LBD for active or prior COVID-19 infection and examining changes in clinical manifestations and diagnostic biomarkers. Within the scope of our parent R01 award and in response to the NIH Notice of Special Interest (NOT-NS-21-037), we propose to consider COVID-19 status as a biological variable in our human subject studies on LBD with concomitant biomarker assessments, to be accomplished in two aims. Aim 1 will examine if COVID-19 infection alters disease severity and progression in LBD patients. LBD patients will be tested for current and prior COVID-19 infection and undergo standardized clinical assessments and neurological evaluations for parkinsonism, cognitive decline, and neuropsychiatric symptoms. Aim 2 will assess changes in diagnostic tissue and neuroimaging biomarkers in LBD patients affected by COVID-19 infection. Our proposed research will provide molecular and neurophysiological insights into the effects of COVID-19 infection on clinical progression of LBD, with the ultimate goal of guiding preventative and therapeutic interventions.

抽象的该补充申请将检查 COVID-19 对疾病严重程度和变化的影响影响美国 140 万人的路易体痴呆 (LBD) 诊断生物标志物最近的研究表明研究表明，痴呆症患者更容易受到 COVID-19 感染，然而，COVID-19 的影响 19感染对痴呆症严重程度和进展的影响尚未得到系统研究。进一步地，它是尚不清楚路易体疾病与报告的 COVID-19 疾病之间的症状有何重叠，包括嗅觉丧失和各种神经系统症状可能会使 LBD 的临床评估和诊断进一步复杂化。我们将通过测试 LBD 患者是否患有活跃或既往的 COVID-19 感染来解决这个研究问题，检查临床表现和诊断生物标志物的变化。在我们母公司 R01 的范围内奖励并响应 NIH 特别关注通知 (NOT-NS-21-037)，我们建议考虑在我们对 LBD 和伴随生物标志物进行的人类受试者研究中，COVID-19 作为生物变量的地位评估，要实现两个目标。目标 1 将检查 COVID-19 感染是否会改变疾病的严重程度 LBD 患者的进展情况。 LBD 患者将接受当前和既往的 COVID-19 感染检测，并且接受针对帕金森症、认知能力下降的标准化临床评估和神经学评估，和神经精神症状。目标 2 将评估诊断组织和神经影像生物标志物的变化受 COVID-19 感染影响的 LBD 患者。我们提出的研究将提供分子和关于 COVID-19 感染对 LBD 临床进展影响的神经生理学见解，最终结果指导预防和治疗干预的目标。